RSS

IMP321

Approval has been granted for the third cohort of Prima BioMed’s Phase I clinical trial of IMP321 in combination with KEYTRUDA, being conducted in Australia. This cohort will recruit six patients with unresectable or metastatic melanoma. more

25 Apr 2017 11:56 News